Clinical Trial Update: A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing mirikizumab to secukinumab and placebo in moderate-to-severe plaque psoriasis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Mirikizumab (mirikizumab)
• Secukinumab (secukinumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2021-03-30